Souhaitez-vous accéder aux communiqués récents ?

HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...

Company announcement no. 6 - 2624 March 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Galapagos is van plan een strategische samenwerking aan te gaan met Gilead, na de overname van Ouro Medicines door Gilead De nieuwe partnerstructuur zou aanzienlijk verbeterde financiële voorwaarden...

Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms...

BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and...

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis...

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned...

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential...

– El éxito de la reunión con la FDA permite avanzar hacia el ensayo clínico de fase 3 propuesto del VCN-01 en combinación con gemcitabina/nab-paclitaxel para el tratamiento de primera línea del ACDP...